Further investigations that study the impact of the BACH2 and BCL6 signalling axis will not only improve our understanding of CLL pathogenesis, but will also offer new opportunities for novel targeted therapy development. The gene discussed is BCL6; the disease is B-cell chronic lymphocytic leukemia.